- In silico predictions of potential mutagenicity / carcinogenicity employing QSAR models accepted by regulatory authorities.
- Risk assessment and qualification strategies for potentially genotoxic impurities in drug candidates as well as marketed pharmaceuticals.
- Genotoxicity risk assessments of medical devices according to ISO 10993.
- Design, monitoring and evaluation of both non-regulatory and regulatory genotox studies.
- Literature and database searches, tailor-made for customer needs.